Timing is everything: new trial seeks to boost cancer treatment by scheduling immunotherapy just right
NCT ID NCT07388836
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether giving the immunotherapy drug toripalimab on different days during chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 198 participants will receive standard chemotherapy plus toripalimab on Day 1, Day 5, or Day 9 of each 3-week cycle. The main goal is to see which timing leads to the highest rate of complete tumor disappearance after two cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (an immunotherapy drug) combined with gemcitabine and cisplatin chemotherapy
- What this could lead to
- If successful, this could identify the best timing for adding immunotherapy to chemotherapy, potentially improving tumor shrinkage and long-term control for patients with advanced nasopharyngeal cancer.
- What could go wrong
- This is an early-phase (Phase II) trial with only 198 participants, so results may not apply to all patients. The study is not yet recruiting, and the optimal timing may not improve outcomes or could increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.